Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  CSL Limited    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
CSL Limited is an Australia-based biotechnology company engaged in the developing and delivering medicines that treat people with rare diseases. It offers treatments for people who are living with conditions in the immunology and neurology; haematology and thrombosis; cardiovascular and metabolic; respiratory, and transplant therapeutic areas. Its segment includes CSL Behring and Seqirus. CSL Behring segment manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products.

Number of employees : 27 000 people.
Sales per Business
20192020Delta
AUD (in Million)%AUD (in Million)%
CSL Behring10,26886.3%11,71586.3% +14.1%
Seqirus1,67214.1%1,93514.3% +15.73%
Sales per region
20192020Delta
AUD (in Million)%AUD (in Million)%
United States5,55746.7%6,85950.5% +23.44%
Rest of World2,44220.5%2,97621.9% +21.87%
Germany1,0689%1,2329.1% +15.34%
Australia981.898.3%1,1228.3% +14.29%
United Kingdom713.696%713.335.3% -0.05%
Switzerland302.032.5%426.333.1% +41.15%
China875.067.4%321.162.4% -63.3%
Managers and Directors
NameAgeSinceTitle
Paul Perreault622013Chief Executive Officer, Executive Director & MD
Brian McNamee632018Chairman
Paul McKenzie-2019Chief Operating Officer
Joy Carolyn Linton552020Chief Financial Officer
Andrew Cuthbertson, Dr.652018Chief Scientific Officer & Executive Director
William Mezzanotte, Dr.-2018Chief Medical Officer, EVP & Head-R&D
Bruce Robert Brook642011Independent Non-Executive Director
Marie McDonald642013Independent Non-Executive Director
Megan Clark, Dr.622016Independent Non-Executive Director
Shah Abbas Hussain552018Independent Non-Executive Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 454,048,707 454,028,492 100.0% 0 0.0% 100.0%
Shareholders
NameEquities%
BlackRock Fund Advisors 14,104,126 3.10%
The Vanguard Group, Inc. 12,503,859 2.75%
Norges Bank Investment Management 5,469,725 1.20%
Vanguard Investments Australia Ltd. 5,139,419 1.13%
BlackRock Investment Management (Australia) Ltd. 4,626,484 1.02%
Fidelity Management & Research Co. LLC 4,443,707 0.98%
WCM Investment Management LLC 4,375,928 0.96%
Capital Research & Management Co. (World Investors) 3,987,792 0.88%
BlackRock Advisors (UK) Ltd. 3,428,750 0.75%
BlackRock Investment Management (UK) Ltd. 3,213,086 0.71%
Company contact information
CSL Ltd.
45 Poplar Road
Parkville, Victoria (VIC) 3052

Phone : +61.3.9389.1911
Fax : +61.3.9389.1434
Web : http://www.csl.com.au